Shares of DexCom DXCM rose 1.15% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 44.62% over the past year to $0.94, which beat the estimate of $0.64.
Revenue of $500,900,000 up by 26.39% from the same period last year, which beat the estimate of $476,750,000.
Outlook
DexCom hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $1,900,000,000 and $1,900,000,000.
Details Of The Call
Date: Oct 27, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/ctub67qk
Price Action
Company's 52-week high was at $456.23
Company's 52-week low was at $145.23
Price action over last quarter: down 10.66%
Company Description
Dexcom designs and commercializes continuous glucose monitoring (CGM) systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company sells three different pieces of equipment, a sensor, a transmitter, and a receiver.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.